Rhone Ma Holdings Bhd banner
R

Rhone Ma Holdings Bhd
KLSE:RHONEMA

Watchlist Manager
Rhone Ma Holdings Bhd
KLSE:RHONEMA
Watchlist
Price: 0.68 MYR -0.73% Market Closed
Market Cap: 150.4m MYR

Relative Value

The Relative Value of one RHONEMA stock under the Base Case scenario is hidden MYR. Compared to the current market price of 0.68 MYR, Rhone Ma Holdings Bhd is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

RHONEMA Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Multiples Across Competitors

RHONEMA Competitors Multiples
Rhone Ma Holdings Bhd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
MY
Rhone Ma Holdings Bhd
KLSE:RHONEMA
150.4m MYR 0.7 11.4 5.5 6.6
US
Eli Lilly and Co
NYSE:LLY
997.2B USD 15.3 48.3 32.5 34.6
US
Johnson & Johnson
NYSE:JNJ
578.6B USD 6.1 21.6 15 18.4
CH
Roche Holding AG
SIX:ROG
281.8B CHF 4.6 30.1 12.7 14.8
US
Merck & Co Inc
NYSE:MRK
303.5B USD 4.7 16.6 10.4 12.1
CH
Novartis AG
SIX:NOVN
231.3B CHF 5.3 21.3 13.1 16.9
UK
AstraZeneca PLC
LSE:AZN
218.1B GBP 5.2 32.1 15.3 22.4
DK
Novo Nordisk A/S
CSE:NOVO B
1.4T DKK 4.5 13.7 10 11.8
IE
Endo International PLC
LSE:0Y5F
218B USD 94 -74.6 333.1 835.4
US
Pfizer Inc
NYSE:PFE
154.7B USD 2.5 19.9 7.4 9.9
US
Bristol-Myers Squibb Co
NYSE:BMY
125.6B USD 2.6 17.8 6.9 8.9
P/E Multiple
Earnings Growth PEG
MY
R
Rhone Ma Holdings Bhd
KLSE:RHONEMA
Average P/E: 23.3
11.4
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
48.3
28%
1.7
US
Johnson & Johnson
NYSE:JNJ
21.6
7%
3.1
CH
Roche Holding AG
SIX:ROG
30.1
29%
1
US
Merck & Co Inc
NYSE:MRK
16.6
14%
1.2
CH
Novartis AG
SIX:NOVN
21.3
15%
1.4
UK
AstraZeneca PLC
LSE:AZN
32.1
38%
0.8
DK
Novo Nordisk A/S
CSE:NOVO B
13.7
7%
2
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -74.6 N/A N/A
US
Pfizer Inc
NYSE:PFE
19.9
26%
0.8
US
Bristol-Myers Squibb Co
NYSE:BMY
17.8
17%
1
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
MY
R
Rhone Ma Holdings Bhd
KLSE:RHONEMA
Average EV/EBITDA: 42
5.5
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
32.5
18%
1.8
US
Johnson & Johnson
NYSE:JNJ
15
2%
7.5
CH
Roche Holding AG
SIX:ROG
12.7
5%
2.5
US
Merck & Co Inc
NYSE:MRK
10.4
7%
1.5
CH
Novartis AG
SIX:NOVN
13.1
9%
1.5
UK
AstraZeneca PLC
LSE:AZN
15.3
10%
1.5
DK
Novo Nordisk A/S
CSE:NOVO B
10
7%
1.4
IE
E
Endo International PLC
LSE:0Y5F
333.1
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.4
-4%
N/A
US
Bristol-Myers Squibb Co
NYSE:BMY
6.9
-13%
N/A